Abiopharma

🔍 Leproust Emily M. (Executive)

Company: GeneDx Holdings Corp. (WGS)

Report Date: 2026-06-18

Detailed Transactions and Holdings:

• Acquired 3,576 shares of Class A Common Stock (Direct)
  Date: 2026-06-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 24,852.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 4,248 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,248.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 3,576 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-18 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
• F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
• F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.